Privately owned Repertoire Immune Medicines announced a partnership worth up to $1.9B with Eli Lilly (LLY) on Thursday to develop and commercialize a new class of treatments targeting autoimmune diseases.
According to the Cambridge, MA-based company, the collaboration focuses on developing tolerizing therapies designed to restore immune homeostasis and create a durable remission, unlike currently available therapies, which are associated with generalized immune suppression.
As part of the deal, Repertoire will be responsible for early development efforts until candidate nomination. Lilly (LLY) will take over clinical development, production, regulatory activities, and potential commercialization.
In exchange, the Indiana-based pharma giant will pay $85M upfront to Repertoire in addition to tiered royalties on net sales, as well as development and commercial milestones worth up to $1.84B.
